ImageJ software (version 1.42q) was used for count yellow and red puncta
Short-term use is rarely effective because the underlying physiological drivers of obesitysuch as hormonal imbalances in appetite regulationoften return once the medication is stopped
With the exception of insulin and FDA-approved GLP-1 medications, researchers have not evaluated most peptide injections in clinical trials for safety, effectiveness, and quality, and these drugs could pose potential health risks
These foundational practices often resolve mild sleep issues without medication adjustment
However, based on the clinical trial criteria used in studies such as the Phase 2 trial published in the New England Journal of Medicine (2023), researchers have investigated its use in adults with: Obesity , defined as a body mass index (BMI) of 30 kg/m or above Overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, or obstructive sleep apnoea Type 2 diabetes , where improved glycaemic control alongside weight reduction is a treatment goal In clinical trials, participants were typically adults without a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)